RGLS - Regulus Therapeutics Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 511.66M
Enterprise Value 37.18M
Trailing P/E N/A
Forward P/E 1-0.28
PEG Ratio (5 yr expected) 1-0.01
Price/Sales (ttm)1.71
Price/Book (mrq)2.46
Enterprise Value/Revenue 31.05
Enterprise Value/EBITDA 6-0.31

Trading Information

Stock Price History

Beta (3Y Monthly) 1.49
52-Week Change 3-82.41%
S&P500 52-Week Change 3-0.33%
52 Week High 34.0800
52 Week Low 30.5000
50-Day Moving Average 30.9176
200-Day Moving Average 31.0724

Share Statistics

Avg Vol (3 month) 3178.97k
Avg Vol (10 day) 396.5k
Shares Outstanding 520.77M
Float 9.88M
% Held by Insiders 117.91%
% Held by Institutions 124.61%
Shares Short (Jul 31, 2019) 4647.26k
Short Ratio (Jul 31, 2019) 43.39
Short % of Float (Jul 31, 2019) 43.80%
Short % of Shares Outstanding (Jul 31, 2019) 43.12%
Shares Short (prior month Jun 28, 2019) 4830.66k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 212/1
Last Split Date 3Oct 4, 2018

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-369.23%

Management Effectiveness

Return on Assets (ttm)-42.12%
Return on Equity (ttm)-357.30%

Income Statement

Revenue (ttm)6.83M
Revenue Per Share (ttm)0.61
Quarterly Revenue Growth (yoy)0.00%
Gross Profit (ttm)-33.87M
EBITDA -23.41M
Net Income Avi to Common (ttm)-27.11M
Diluted EPS (ttm)-2.4300
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)19.57M
Total Cash Per Share (mrq)0.94
Total Debt (mrq)15.09M
Total Debt/Equity (mrq)318.09
Current Ratio (mrq)1.18
Book Value Per Share (mrq)0.23

Cash Flow Statement

Operating Cash Flow (ttm)-25.59M
Levered Free Cash Flow (ttm)-15.27M